Medicinal Under-Treatment Costs Germany Heavily, Says Study
Posted on: Thursday, 21 February 2008, 12:00 CST
A study which was conducted on behalf of the German association of research-based pharmaceutical companies or VFA has revealed that under-treatment of patients has resulted in escalation of healthcare costs in Germany, according to scripnews.com.
As per the study results that were assessed for a 10-year period, under-treatment of depression led to annual costs of E17.9 billion, of which direct costs made up Euro6.2 billion and indirect costs amounted to Euro11.7 billion. While under-treatment of rheumatoid arthritis cost E6.8 billion annually, osteoporosis cost E3.6 billion. It was also found that under treatment of patients led to mushrooming of healthcare costs through longer hospital stays, rehabilitation, disability, incapacity to work and early retirement.
According to Cornelia Yzer, chief of VFA, the inordinate prescription of drugs by doctors and insufficient allotment of funds (only 6.3% of the money spent on pharmaceuticals goes to innovative medicines) have contributed to the rising healthcare costs in Germany.
Source: Datamonitor
Related Articles
- Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems
- External Beam Partial Breast Irradiation Is The Most Cost-Effective Treatment
- Offshore Texas Oil Port to Cost $2 Billion
- Calcium and Vitamin D Could Reduce Hip Fractures and Save Billions in Healthcare
- Employee Retention at Yahoo Could Cost Billions
- South Korea Spends An Estimated $49 Billion On Healthcare Each Year
- Business Objects Launches Activity Based Costing Solution for Healthcare
- Web-Based Staffing Solution Provides Low Cost Solution to Healthcare Staffing Crisis
- The Burden of Illness Associated With Psoriasis: Cost of Treatment With Systemic Therapy and Phototherapy in the US
- Adult ADHD Costs Billions in Lost Income
 |
 |
User Comments (0)
RSS Feeds